Sponsor content

Collaborative Research and Licensing Opportunity: Synergistic Internal Ribosomal Entry Site (IRES) - MicroRNA-Based Approach for Attenuation of Flaviviruses and Live Vaccine Development

Available technology comprises live attenuated flavivirus vaccines, live attenuated multivalent flavivirus vaccines, and methods of preventing flavivirus infections as well as methods of making the vaccines.

Many members of the Flaviviridae family are emerging and reemerging human pathogens that have caused outbreaks of devastating and often fatal diseases and represent a serious public health problem on a global scale.There is no single attenuation strategy that exists which is sufficient to prepare a safe, efficacious and immunogenic live attenuated virus vaccine that will work universally for Flaviviridae.This patent application claims live attenuated flavivirus vaccines, live attenuated multivalent flavivirus vaccines, and methods of preventing flavivirus infections as well as methods of making the vaccines claimed in the application.More specifically, this patent application claims methods for attenuating a flavivirus or chimeric flavivirus using a synergistic dual strategy involving inserting miRNA-targeting sequences to restrict virus replication in target hosts, cells and/or tissues and placing one or more flavivirus genes under translational control of an internal ribosomal entry site (IRES).

Potential Commercial Applications:

  • Diagnostics
  • Vaccines

Competitive Advantages:

  • Potential one-dose flavivirus vaccine
  • Ease of manufacture in Vero cells
  • Low-cost potential vaccine
  • Developing and developed world potential vaccines

Development Stage:

In vivo data available (animal)

Intellectual Property:

HHS Reference No. E-006-2017/0: U.S. Provisional Application No. 62/443,214, filed January 6, 2017.

Collaborative Research Opportunity:
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a therapeutic, diagnostic or vaccine for Norovirus infections.

Contact:

Please contact Peter Soukas, J.D., 301-594-8730; peter.soukas@nih.gov.

Go to the profile of NIAID Technology Transfer and Intellectual Property Office

NIAID Technology Transfer and Intellectual Property Office

NIAID’s technology transfer office, TTIPO, is a one-stop resource for organizations interested in partnering with NIAID to access, develop, and manage the translation of research discoveries into medically beneficial products. TTIPO seeks to expand NIAID’s innovation pipeline with existing and new partners in areas such as newly emerging and re-emerging infectious diseases (e.g., dengue, Zika, Ebola, influenza, methicillin-resistant Staphylococcus aureus and HIV/AIDS), biodefense (e.g., smallpox and anthrax), and immune-mediated diseases (e.g., asthma and allergy).

No comments yet.